IQ-AI Subsidiary Launches Hopeful Brain Tumor Treatment Program

IQ-AI Limited (GB:IQAI) has released an update.

IQ-AI Limited’s subsidiary, Imaging Biometrics, has launched an Expanded Access Program for gallium maltolate, a treatment for recurrent brain tumors, after receiving FDA approval. The program offers hope to patients with glioblastoma who are unable to participate in clinical trials by providing access to this investigational therapy. CEO Trevor Brown emphasizes the potential benefit to patients given the positive safety results from ongoing clinical studies.

For further insights into GB:IQAI stock, check out TipRanks’ Stock Analysis page.